Expertise in
18
conditions

Dr. Roger Lyons

Hematology
Texas Oncology Pharmacy San Antonio
5206 Research Dr, 
San Antonio, TX 
Offers Telehealth
Expertise in
18
conditions
Texas Oncology Pharmacy San Antonio
5206 Research Dr, 
San Antonio, TX 

Overview

Roger Lyons is a Hematologist in San Antonio, Texas. Dr. Lyons is highly rated in 18 conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Idiopathic Neutropenia, Agranulocytosis, Chronic Familial Neutropenia, and Splenectomy.

His clinical research consists of co-authoring 44 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Scott and White Health
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 5 Less Insurance Carriers -

Locations

Texas Oncology Pharmacy San Antonio
5206 Research Dr, San Antonio, TX 78240

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: February 03, 2026
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)
Single-arm, Open Label, Phase II Study of MBG453 (Sabatolimab) Added to FDA Approved Hypomethylating Agents of Investigator's Choice (IV/SC/Oral) for Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria (US Multi-center) (STIMULUS MDS-US)
Enrollment Status: Terminated
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: MBG453, Azacitidine, Decitabine, INQOVI
Study Phase: Phase 2
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 4
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide
Study Phase: Phase 2
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Combination product
Study Drugs: Alvocidib, Decitabine, Azacitidine
Study Phase: Phase 1/Phase 2
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Enrollment Status: Terminated
Publish Date: October 13, 2023
Intervention Type: Drug
Study Drug: Brentuximab
Study Phase: Phase 2
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: April 26, 2022
Intervention Type: Drug
Study Drug: PT-112
Study Phase: Phase 1
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Enrollment Status: Completed
Publish Date: July 21, 2021
Intervention Type: Drug
Study Drug: Fostamatinib
Study Phase: Phase 2
View 9 Less Clinical Trials

44 Total Publications

Treatment patterns and overall survival among patients with myelodysplastic syndromes treated in the US community oncology setting: a real-world retrospective observational study.
Treatment patterns and overall survival among patients with myelodysplastic syndromes treated in the US community oncology setting: a real-world retrospective observational study.
Journal: Leukemia & lymphoma
Published: December 13, 2025
Similar Doctors
Expertise in
8
conditions
Dr. Robyn Scherber
Hematology
Expertise in
8
conditions
Dr. Robyn Scherber
Hematology

University Of Texas Health Science Center At San Antonio

7979 Wurzbach Rd, 
San Antonio, TX 
 (259.2 miles away)
210-450-1406
Languages Spoken:
English
See accepted insurances

Robyn Scherber is a Hematologist in San Antonio, Texas. Dr. Scherber is highly rated in 8 conditions, according to our data. Her top areas of expertise are Myeloproliferative Neoplasms (MPN), Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, and Bone Marrow Transplant.

Expertise in
15
conditions
Dr. Montaser Shaheen
Hematology
Expertise in
15
conditions
Dr. Montaser Shaheen
Hematology

University Of Texas Health Science Center At San Antonio

7979 Wurzbach Rd, 
San Antonio, TX 
 (259.2 miles away)
210-450-9000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Montaser Shaheen is a Hematologist in San Antonio, Texas. Dr. Shaheen is highly rated in 15 conditions, according to our data. His top areas of expertise are Melanoma, Neuroendocrine Tumor, Adult Soft Tissue Sarcoma, and Undifferentiated Pleomorphic Sarcoma.

Expertise in
16
conditions
Dr. Ildefonso Rivera
Hematology | Oncology
Expertise in
16
conditions
Dr. Ildefonso Rivera
Hematology | Oncology

Office

2829 Babcock Rd Ste 300, 
San Antonio, TX 
 (259.3 miles away)
210-580-9500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ildefonso Rivera is a Hematologist and an Oncologist in San Antonio, Texas. Dr. Rivera is highly rated in 16 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Gastric Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Follicular Lymphoma.

Frequently Asked Questions about Dr. Roger Lyons

How do I make an appointment with Dr. Roger Lyons?

You can book an appointment with Dr. Roger Lyons by calling their office at 210-595-5300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Roger Lyons a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Roger Lyons is classified as an Distinguished expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Roger Lyons specialize in?

While Dr. Roger Lyons is a Hematology, they have specific expertise in Myelodysplastic Syndrome (MDS), Idiopathic Neutropenia, and Agranulocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Roger Lyons participate in research or clinical trials?

Yes. Dr. Roger Lyons has published 44 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Dr. Roger Lyons's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Roger Lyons accept my insurance?

Dr. Roger Lyons accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 210-595-5300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lyons's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile